Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAN-301
- Development stage
- Unknown
- Lead developer
- Valin Technologies
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
VAN-301 is a recombinant fusion protein biologic being developed by Valin Technologies, in partnership with Sinopharm, for the treatment of plaque psoriasis and ankylosing spondylitis. The molecule consists of the extracellular domain of the human IL-17A receptor fused to the Fc region of a human IgG1 antibody. It acts as a soluble decoy receptor that binds to the pro-inflammatory cytokine IL-17A with high affinity, preventing it from interacting with its endogenous cell-surface receptors. By neutralizing IL-17A, VAN-301 inhibits the downstream signaling pathways that drive inflammation and tissue damage in autoimmune conditions. The drug is currently in Phase 1 clinical development.
- Other names
- IL-17A receptor extracellular domain-IgG1 Fc fusion proteinIL17A receptor extracellular domain-IgG1 Fc fusion proteinIL 17A receptor extracellular domain-IgG1 Fc fusion protein
02
Targets
IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on VAN-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAN-301.